Low-dose interleukin 2 for the reduction of vascular inflammation in acute coronary syndromes (IVORY): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase II clinical trial. (2022)

First Author: Sriranjan R
Attributed to:  Low dose interleukin (IL)-2 in patients with a recent acute coronary syndrome funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1136/bmjopen-2022-062602

PubMed Identifier: 36207050

Publication URI: http://europepmc.org/abstract/MED/36207050

Type: Journal Article/Review

Volume: 12

Parent Publication: BMJ open

Issue: 10

ISSN: 2044-6055